Pharmacokinetic (PK) interactions between capecitabine (X), oxaliplatin (O) and bevacizumab (A) when used in combination for first-line treatment of metastatic colorectal cancer (MCRC)
Barbara J. Brennan(Roche (Switzerland)), S Choudhury(Hochschule Hannover), Bindi Dhesy-Thind(Roche (Switzerland)), Katherine Smith(Barts Health NHS Trust), Sohail Hussain(Jazan University), C. Cripps(Canadian Partnership Against Cancer), Maryline Abt(Roche (Switzerland)), Karen Rittweger(Roche (Switzerland)), A. Gandhi(Roche (Switzerland)), Lillian L. Siu(University Health Network)
Cited by 5
Related Papers
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer
|New England Journal of Medicine|2018|2.9k
Dose Escalation Methods in Phase I Cancer Clinical Trials
|JNCI Journal of the National Cancer Institute|2009|856
Toward understanding and exploiting tumor heterogeneity
|Nature Medicine|2015|770
Small molecules, big impact: 20 years of targeted therapy in oncology
|The Lancet|2020|606